Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Legend Biotech CorporationNASDAQ: LEGN

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax turns positive

Q3 FY2026 income before tax was $49.4M, compared with -$39.07M a year earlier. Trailing-twelve-month income before tax was $32.2M.

Context

  • Income before tax amounted to 27.5% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near $49.4M or moves back toward the trailing-twelve-month quarterly average of $8.05M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$49.4M-11.0% QoQ
Last fiscal yearDec 2025
-$282.6M-78.7% YoY
LTMSep 2026
$32.2M+114.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+226.4%——
1 year-78.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(282.6M) USD
Year-over-year change
-78.7%

Income Before Tax vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 income before tax of $32.2M is the highest of the 11 companies compared; the peer median is -$131.84M.
  • Its year-over-year change of +114.5% is the highest of 11, against a peer median of -2.8%.
  • Income before tax amounts to 2.4% of revenue for LEGN, versus a peer median of 752.7%.
LEGN Competitors Peer median
Income Before Tax for LEGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M +114.5%—2.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$9.44M +39.8%—40.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$44.49M -102.3%—98.7%
CLLSCellectis S.A.LTM Mar 2026-$69.45M -15.2%—102.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$107.85M -435.1%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M +26.1%—2056.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$133.77M +9.5%—1194.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$160.97M -323.3%—9068.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M +31.0%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M +26.3%—794858.1%
AUTLAutolus Therapeutics plcLTM Mar 2026-$288.22M -23.0%—311.3%
Peer median (excluding LEGN) -$131.84M-2.8%—752.7%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.